Frankfurt am Main, Germany

Nils Poth

USPTO Granted Patents = 2 

Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2020-2021

Loading Chart...
2 patents (USPTO):

Title: Nils Poth: Innovator in GLP-1/Glucagon Dual Agonist Research

Introduction

Nils Poth is a notable inventor based in Frankfurt am Main, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of conjugates that involve GLP-1 and glucagon receptor agonists. His innovative work has led to the filing of two patents, showcasing his expertise and dedication to advancing medical science.

Latest Patents

Nils Poth's latest patents include groundbreaking inventions related to conjugates comprising a GLP-1/glucagon dual agonist, a linker, and hyaluronic acid. The first patent describes a conjugate or a pharmaceutically acceptable salt that includes a GLP-1/glucagon receptor agonist, a linker, and a hyaluronic acid hydrogel. This invention aims to provide a medicament for treating or preventing diseases that can be addressed by GLP-1/glucagon receptor agonists. The second patent also focuses on similar conjugates, emphasizing the innovative use of linker moieties and their potential therapeutic applications.

Career Highlights

Nils Poth has established himself as a key figure in pharmaceutical research, particularly through his work at Sanofi. His contributions to the field have been recognized through his patents, which reflect his commitment to developing effective treatments for various medical conditions. His innovative approach to drug formulation and delivery has positioned him as a valuable asset in the industry.

Collaborations

Nils has collaborated with esteemed colleagues such as Dieter Kadereit and Michael Wagner. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further enhancing the quality of their research and innovations.

Conclusion

Nils Poth's work in the field of GLP-1/glucagon dual agonists exemplifies the impact of innovative research on pharmaceutical development. His patents and collaborations highlight his commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…